Keepers

[Mean Weimaraner]

$IMUN Immune Therapeutics .05206 0.00906 (21.07%)

investorshub.advfn.com/boards/read_msg.aspx?message_id=130485383

As the largest economy in West Africa, our Lodonal approval in Nigeria allows us to fast track all of the 15 countries in West Africa. Senegal has accepted our New Drug Application for Lodonal. We are seeking approval for three indications. We are on schedule for drug approval in many of the countries that make up the Economic Community of West Africa States (“ECOWAS”) and expect to solidify several of them in 2017.

*2017: Focus on Revenues, Trials, IP and Achieving Profitability*

New IP. In 2016, we filed for three new patents surrounding Lodonal and Met-Enkephalin (“MENK”), and published our research in six medical journals.

Revenue and Cash Flow. We expect to commercialize Lodonal in Nigeria, and other West African nations during the first half of 2017. Our internal projections indicate this will generate several million dollars in revenue, at a healthy gross margin, for growing positive cash flow. That cash flow will fund conducting other clinical trials and securing regulatory approvals in other African Nations for additional indications including malaria, opportunistic infections and cancer. Our goal is to be able to fully self-fund our growth by the end of 2017.

NAFDAC Marketing Approval. Drug approval does not provide marketing approval, but with the approval of Lodonal by the DR Minister of Health we can now finalize our application for marketing with Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC). The final remaining step is for NAFDAC officers to complete a GMP audit of the facility in Santo Domingo, and this is anticipated by mid-2017. With that, we fully expect to begin distribution and sales in Nigeria with other West African countries to follow.

Cytocom Inc. is our affiliate clinical-stage pharmaceutical company focused on advancing IRT-103 (US FDA designator for ‘Lodonal’). It is responsible for the development of our patented therapies with the FDA and EMA. It will lead the US and EMA (“European Medical Association”) clinical trials on IRT-103 including for Crohn’s disease.

Advance IMUN’s Growing Drug Pipeline. We have started our second clinical for Lodonal as an adjunct treatment for cancer in Malawi, which is slated for completion in mid-2017, with results to be published in the second half of the year. We also plan a bridging trial with MENK for cancer in Nigeria, capitalizing on our strong relationship with NAFDAC -– amongst other clinical trials being developed or planned.

Increase the IP Portfolio. We will continue to protect the value of our clinical research by building intellectual property value as an asset, thus erecting barriers to entry. We filed two new patents surrounding Lodonal in 2016.

Establish a Solid Base of Operations in China. Our Chief Science Officer and Vice Director of the Institute of Immunology, China Medical University in Shenyang, China have been treating patients with MENK and our new cocktail therapy throughout 2016 with positive results. Now that our patents are filed for the cocktail, we plan to publish results in 2017 as part of a larger initiative to advance clinical trials, and establish a solid beachhead in this nation of 1.4 billion people as a gateway to Asia. Our goal is to open our cancer clinic in China to treat patients by year-end 2017.

https://www.otcmarkets.com/stock/IMUN/news/UPDATE----Immune-Therapeutics-Issues-Special-Letter-to-Shareholders?id=149724&b=y

Share Structure-
Authorized Shares
500,000,000 a/o Mar 31, 2017

Outstanding Shares
275,640,164 a/o Mar 31, 2017

-Restricted
130,286,587 a/o Mar 31, 2017

-Unrestricted
145,353,577 a/o Mar 31, 2017

Confidence continues to build in our company as, in 2016, our ‘insider’ management and major shareholders continued to add to their IMUN position through both open market purchases and direct investments into the Company.